CONCOMITANT ADMINISTRATION OF DEFERASIROX WITH MIDAZOLAM RESULTS IN DECREASED SERUM CONC. OF MIDAZOLAM WHILE INCREASED CONC OF REPAGLINIDE & THEOPHYLLINE.
CONCOMITANT ADMINISTRATION OF DEFERASIROX WITH RIFAMPICIN & CHOLESTYRAMINE CAUSED DECREASED PLASMA CONC OF DEFERASIROX.
CYTOCHROME P450 ENZYMES: DEFERASIROX INHIBITS HUMAN CYP3A4, CYP2C8, CYP1A2, CYP2A6, CYP2D6, AND CYP2C19 IN VITRO.